N
Novareus
Air dis-infection devices powered by NanoStrike; the first line of protection against airborne viruses & bacteria
About Novareus
Novaerus is part of WellAir – a leading provider of infection control solutions. WellAir makes the indoor world cleaner and safer. It's that important. Scientifically proven to harmonize with how we work, live, learn and play. Innovation in Air Disinfection For over a decade, Novaerus has been providing medical-grade solutions that address a global problem; unhealthy indoor air. Indoor air is the culprit for many virus-based illnesses, bacterial infections, asthma, allergies and a host of long-term health issues.
Led by a dedicated and highly skilled team of scientists, we took a fundamentally different approach to air dis-infection, which led to the transformational discovery of NanoStrike - the unique, patented technology at the core of all Novaerus portable air dis-infection devices today. This nanotechnology inactivates all airborne microorganisms on contact providing the first line of protection against viruses and bacteria.
Utilizing NanoStrike technology, Novaerus air disinfection devices help to prevent the spread of infection in thousands of hospitals, senior living facilities, IVF clinics, dental offices, schools and homes around the world.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2011
- Headquarters
- Dublin, Ireland
- Open positions
- None listed
- Dealroom signal
- 26.3/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Healthcare Services, Biotechnology, Retailers and Manufacturers, Medical Systems, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing, Marketplace & ecommerce
- Client focus
- b2c
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Feb 2016 | $15M | $59M | Fidelity Investments · Summit Bridge Capital | — |
| SEED✓Equity / VC | Dec 2015 | — | — | Summit Bridge Capital · F-Prime · Polaris Partners | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Novareus is 310 monthly website visits, down 83.7% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Summit Bridge Capital
Series A3 investors entered at this stage
Other known investors4 additional known investors
Atlantic Bridge
Eight Roads Ventures
Jason Lin
WestSummit Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Novareus on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Novareus’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.